Pan Pacific Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Xiangmin Cui's vision, in co-founding Pan Pacific Pharmaceuticals two years ago, was to combine his personal knowledge of traditional Chinese medicines with the scientific training he received both in China and at Stanford University. Pan Pacific's lead compound for rheumatoid arthritis has been successfully cloned and expressed, and shown to be identical in structure and activity to a naturally occurring molecule with potency against the disease.
You may also be interested in...
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”
The New Antibodies Revolutionizing Medicine
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.
What Next In Oncology?
Oncology dominates pharma sales and pipeline league tables. But where is the next Keytruda?